ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "T Cell"

  • Abstract Number: L03 • ACR Convergence 2024

    CD9 Expressing T Follicular Helper Cells Are a Highly Functional Subset Expanded in Systemic Lupus Erythematosus

    Kyleigh Brimmer1, Olivia Antao1, Daniel Mayer1, Gina Sanchez1, Rebecca Francis1, Htay Htay Kyi2, Mary Salim2, Boyan Xia2, Eugenio Capitle2 and Jason Weinstein1, 1Center for Immunity and Inflammation, Rutgers New Jersey Medical School, Newark, NJ, 2Division of Allergy, Immunology and Rheumatology, University Hospital, Newark, NJ

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by the generation of autoantibodies that promote tissue injury. The development of pathogenic autoantibody-secreting B cells in lupus…
  • Abstract Number: L16 • ACR Convergence 2024

    Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial

    Megan Clowse1, David Isenberg2, Joan Merrill3, Thomas Dörner4, Michelle Petri5, Edward Vital6, Eric Morand7, Teri Jimenez8, Stephen Brookes9, Janine Gaiha-Rohrbach10, Christophe Martin11, Annette Nelde12 and Christian Stach13, 1Division of Rheumatology and Immunology, Duke University, Durham, NC, 2Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine, University College London, London, United Kingdom, 3Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Department of Medicine/Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, 5Johns Hopkins University School of Medicine, Baltimore, MD, 6Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 7Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, 8UCB, Raleigh, NC, 9Biogen, Maidenhead, United Kingdom, 10Biogen, Cambridge, MA, 11UCB, Slough, United Kingdom, 12Biogen, Baar, Switzerland, 13UCB, Monheim am Rhein, Germany

    Background/Purpose: Dapirolizumab pegol (DZP) is a novel, polyethylene glycol (PEG)-conjugated antigen-binding (Fab') fragment, lacking an Fc domain, that inhibits CD40L signaling. By binding to CD40L,…
  • Abstract Number: 0003 • ACR Convergence 2024

    CLN-978, a CD19-directed T Cell Engager (TCE), Leads to Rapid and Deep B Cell Depletion and Has Broad Potential for Development in Autoimmune Diseases

    Máire F. Quigley1, Jennifer S. Michaelson1, Jeffrey Jones1, Farrukh T. Awan2, Geoffrey P. Shouse3, Yue Zhang1, Todd Shearer1, Judy Inumerable1, Irina M. Shapiro1, Patrick A. Baeuerle1 and Stephen Wax1, 1Cullinan Therapeutics, Inc., Cambridge, 2UT Southwestern Medical Center, Dallas, 3City of Hope Comprehensive Cancer Center, Duarte

    Background/Purpose: CD19-directed CAR T cell therapy has been reported to induce profound B cell depletion and deep clinical responses, including drug-free remission, in patients with…
  • Abstract Number: 0499 • ACR Convergence 2024

    PD-1hiCXCR5-CD4+T Peripheral Helper Cells Enrich in Rheumatoid Arthritis and Predict Clinical Response to Anti-TNF Treatment

    Wanki Ho1, Huaqun Zhu1, Hua Ye1, Dongdong Fu2 and Xi Xu1, 1Peking University People's Hospital, Beijing, China, 2Xinxiang Central Hospital, Xinxiang, Henan, China (People's Republic)

    Background/Purpose: PD-1hiCXCR5-CD4+T peripheral helper cells (Tph) are newly identified pathogenic CD4+T helper cells and participate in rheumatoid arthritis (RA) pathogenesis. However, the clinical significance of…
  • Abstract Number: 1134 • ACR Convergence 2024

    First-in-Human Evaluation of the Safety, Tolerability and Pharmacokinetics of the T Cell Receptor Signal Modulator AX-158

    Christopher VanDeusen1, Andres Gagete1, Annelize Koch2 and D Scott Batty Jr1, 1Artax Biopharma, Inc, Cambridge, MA, 2Simbec-Orion, Merthyr Tydfil, Wales, United Kingdom

    Background/Purpose: Nck is a cytosolic protein that binds a domain of the T cell receptor (TCR) following TCR interaction to amplify responses from low affinity…
  • Abstract Number: 1785 • ACR Convergence 2024

    Comparative Immuno-Metabolomics Shows Singular Changes in Systemic Lupus Erythematosus Metabolic Phenotype Induced by T-Cell Activation

    Martin Stradner1, Fernanda Monedeiro2, Elmar Zuegner2, Barbara Prietl3, Monika Oberhuber4, Michael Khalil5, Christoph Magnes2, Hans-Peter Brezinsek1, Angela Libiseller3 and Thomas Pieber3, 1Div. of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, 2Joanneum Research, Graz, Austria, 3Div. of Endocrinology, Medical University of Graz, Graz, Austria, 4CBmed, Graz, Austria, 5Dept. of Neurology, Medical University of Graz, Graz, Austria

    Background/Purpose: Metabolic processes have a critical role in regulating immune cell function, therefore being relevant to understanding the pathogenesis and progression of autoimmune diseases.  Here…
  • Abstract Number: 1850 • ACR Convergence 2024

    Exhausted T-cells Are Increased in Autoimmune Diseases and Predict Response to Anti-TNF in RA and SPA Patients

    Samuel Bitoun1, Marie Naigeon2, Matthieu Roulleaux- Dugage2, Caroline De Oliveira2, Caroline Berthot2, Xavier Mariette3, Gaetane Nocturne3 and Nathalie Chaput-Gras2, 1Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicetre, France, 2Laboratoire d'immunomonitoring en Oncologie, INSERM US23, CNRS UMS 3655, Gustave Roussy,, Villejuif, France, 3Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France

    Background/Purpose: Exhaustion can occur after prolonged activation of T cells limiting their immunosurveillance function leading to cancer emergence. Among the exhaustion markers expressed on T…
  • Abstract Number: 1988 • ACR Convergence 2024

    A Randomized, Open-Label Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants

    Marta Cossu1, Carolina Bobadilla Mendez2, Amanda Jackson3, Eugene Myshkin4, Grace Liu5, Edwin Lam6, Ulf H. Beier2, Kathleen Weisel2, Brittney Scott2, Jocelyn H. Leu6, Sheng Gao2 and Dessislava Dimitrova2, 1Janssen Pharmaceutical Research and Development, a Johnson & Johnson company, Leiden, Netherlands, 2Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, 3Janssen Research & Development, LLC, La Jolla, CA, 4Janssen Research & Development, LLC, a Johnson & Johnson company, Cambridge, MA, 5Janssen Research & Development, LLC, a Johnson & Johnson company, Raritan, NJ, 6Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, PA

    Background/Purpose: Nipocalimab is a human IgG1 monoclonal antibody targeting the neonatal Fc receptor (FcRn) that selectively reduces IgG levels without impacting antigen presentation, T- and…
  • Abstract Number: 0004 • ACR Convergence 2024

    Beyond Antibodies and CAR-T: Topologically Engineered, Superdimeric Antibody NK Engagers and T Cell Engagers for B Cell Depletion Demonstrating Cooperative Binding to Target and Effector Cells

    Daniel Capon, Larisa Troitskaya, Marina Fomin, Brendon Frank, Ursula Edman, Benjamin Capon, Brian Law, Steven Chapin, Gavin Lewis, Malcolm Gefter, Juha Punnonen and Nelson Chan, Hinge Bio, Inc., Burlingame, CA

    Background/Purpose: The dramatic demonstration of CD19 CAR-T efficacy in systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, and systemic sclerosis by Georg Schett and colleagues (F.…
  • Abstract Number: 0512 • ACR Convergence 2024

    Co-stimulatory Blockade Causes Targeted Quantitative and Clonotypic Contractions in Extrafollicular B-cell Subsets in Seropositive RA Patients

    Jasmine Shwetar1, William Rigby2, Sladjana Skopelia-Gardner3, Abhimanyu Armarnani1, Kelly Ruggles1 and Gregg Silverman1, 1NYU Grossman School of Medicine, New York, NY, 2Dartmouth-Hitchcock, Norwich, VT, 3Dartmouth Hitchcock Medical Center, Hanover, NH

    Background/Purpose: Of all approved biologic therapies, other than anti-CD20 depletion only CTLA4-Ig/abatacept treatment reduces levels of pathologic autoantibodies. Herein, our primary goal has been to…
  • Abstract Number: 1381 • ACR Convergence 2024

    Elimination of CD45RChigh T and B Cells by anti-CD45RC mAb Lead to Efficient Control of Experimental Rheumatoid Arthritis

    Cécile Bergua1, Marine Besnard1, Ghenima Ahmil2, Laure-Helene Ouisse2, Nadège Vimond1, Apolline Salama2, Bérangère Evrard2, Elise Brisebard3, Alexis Collette1, Fréderic Blanchard4, Thibault Larcher3, Ronald Van Brempt1, Benoit Le Goff5, Ignacio Anegon2 and Carole Guillonneau1, 1AbolerIS Pharma, Nantes, France, Nantes, France, 2Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, CNRS, Nantes, France, Nantes, France, 3APEX-UMR703 PAnTher INRA/ONIRIS, France, Nantes, France, 4INSERM UMR1229, Nantes, France, Nantes, France, 5CHU Nantes, France, Nantes, France

    Background/Purpose: CD45RC is an isoform of CD45, a transmembrane tyrosine phosphatase, essential regulator of T and B cells antigen receptor signaling, expressed by most blood…
  • Abstract Number: 1790 • ACR Convergence 2024

    Response Gene to Complement-32 Expression Is Upregulated in Lupus T Cells and Promotes Th17 Differentiation

    Violeta Rus1, Vinh Nguyen1, Alexandru Tatomir1, Cornelia Cudrici2 and Horea Rus1, 1University of Maryland at Baltimore, Baltimore, MD, 2National Institute of Health, Bethesda, MD

    Background/Purpose: RGC (Response Gene to Complement)-32 is a cell cycle regulator expressed in normal tissues, tumors and a variety of cell lines.  RGC-32 plays a…
  • Abstract Number: 1852 • ACR Convergence 2024

    Uncovering a MAIT-Treg Axis in Skin UV Response: Implications for Photosensitive Reactions in Cutaneous Lupus Erythematosus

    Grace Crossland1, Lindsay Mendyka2, Kaitlyn Dowling3, Michael Constantinides4 and Sladjana Skopelja-Gardner1, 1Dartmouth Geisel School of Medicine, Lebanon, NH, 2Dartmouth Hitchcock Memorial Hospital, Lyme, NH, 3Dartmouth College, Lebanon, NH, 4Scripps Research Institute, San Diego, CA

    Background/Purpose: Approximately 80% of cutaneous lupus erythematosus (CLE) patients experience sensitivity to ultraviolet (UV) sunlight rays, which leads to disfiguring skin lesions or systemic disease…
  • Abstract Number: 2004 • ACR Convergence 2024

    Rheumatic Complications Post-CAR-T Cell Therapy. Experience of a Single Center

    Jose Alfredo Gomez-Puerta1, Ana Monegal1, Andrés Ponce2, Pilar Peris3, Nuria Martínez4, Valentin Ortiz-Maldonado4, Ana Triguero4, Carlos Fernández de larrea4, Julio Delgado4, Raimon Sanmartí Sala1 and Manuel Juan5, 1Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain, 2Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, 3Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, 4Haematology Department, Hospital Clinic of Barcelona, Barcelona, Spain, 5Immunology Department, Hospital Clinic of Barcelona, Barcelona, Spain

    Background/Purpose: CAR-T cell therapy is a promising treatment for a range of systemic autoimmune diseases such as systemic lupus erythematosus, systemic sclerosis, and antisynthetase syndrome,…
  • Abstract Number: 0008 • ACR Convergence 2024

    Preclinical Development and Manufacturability of KYV-201, an Investigational Allogeneic Anti-CD19 Chimeric Antigen Receptor T Cell for the Treatment of Autoimmune Disease

    Ashley Mahne1, Ryan Rodriguez2, Jessica Wang1, Daniel Anaya1, Joseph K. Cheng1, Brandon Kwong1, Jesus Banuelos3, Peter Starokadomskyy3, Soo Park3, Candice Gibson4, Shouvonik Sengupta1, Simone Sandoval1, Jazmin Bravo3, Jeanne Flandez1, Shairaz Shah1, Amanda Goodsell1, Nicole Khoshnoodi1, Jennifer Zeng1, Santiago Foos-Russ1, Mario Lorente1, Jennifer Adrian1, Timothy Klasson1, Yong Zhang5, Jessica Seitzer6, Birgit Schultes5 and Tom Van Blarcom3, 1Kyverna Therapeutics, Inc., Emeryville, CA, 2Kyverna Therapeutics, Inc., Emerville, CA, 3Kyverna Therapeutics, Inc., Emeryville, 4Kyverna Therapeutics, Inc., Emerybille, 5Intellia Therapeutics, Inc., Cambridge, MA, 6Intellia Therapeutics, Inc., Cambridge

    Background/Purpose: Autologous anti-CD19 chimeric antigen receptor (CAR) T cells show early clinical evidence of safety and efficacy for treating several autoimmune diseases (Müller F. N Engl…
  • 1
  • 2
  • 3
  • …
  • 21
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology